Abstract: The invention relates to a system for annotating car radar data, comprising: at least one radar arranged on a car for producing a radar image by means of radar measurement; at least one optical detection system arranged outside the car for producing a camera image; a segmentation unit, which is designed to subject a camera image produced by the optical detection system to semantic segmentation for forming a semantic grid in order to assign one of a plurality of object classes to the camera image pixel by pixel; a computing unit, which is designed to transfer the camera image and/or the radar image into a common coordinate system for co-registration; and an annotation unit, which is designed to carry out annotation of the radar image, in other words to allocate an object class to a radar target of the radar image, in such a way that the object class of the semantic grid of the co-registered camera image in which the radar target of the co-registered radar image is located is allocated to a particular radar tar

Abstract: Estimating the ego-motion of a vehicle, e.g., the self-motion of the vehicle, can be improved by pre-processing data from two or more radars onboard the vehicle using a processor common to the two or more radars. The common processor can pre-process the data using a velocity vector processing technique that can estimate a velocity vector at each point of a predefined number of points, such as arranged in a grid in the field-of-view of radars, with coordinates (X, Y, Z (optional)), where U is the component of the velocity in the X-direction, V is the component of the velocity in the Y-direction, and W is the component of the velocity in the optional Z-direction.

Abstract: A method for signal processing of radar signals of a radar system (100) has at least two radar units (10, 20) arranged at a known distance from one another. At least one spatial field of vision (FoV) of the radar system (100) is captured with radar signals of the at least two radar units (10, 20). A discrete total coordinate system is generated from the field of vision (FoV). Measurement data of the at least two radar units (10, 20) of the radar system (100) generated by the detection of the field of vision (FoV) are co-registered. A multidimensional, vector velocity ({right arrow over (v)}) for at least one resolution cell of the discrete total coordinate system and/or a multidimensional, vector velocity ({right arrow over (v)}100) for the radar system (100) are generated.

Abstract: The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products.

Abstract: The invention relates to a functional part of an electronic piston stroke pipette with an operating environment adapted to manual piston stroke pipettes. The piston stroke pipette according to the invention comprises a pipette cone, in which there is a movable piston, rigidly connected with a transmission for its upwards and downwards movements via a piston rod, in which context the transmission is propelled by a drive motor and wherein the control board comprises an upper part as the operating part for turning and pressing and a bar as a cylindrical connection to the electronics, with the control board and display integrated in the display housing in the upper part and drive motor and battery (rechargeable battery) in the lower part of the pipette housing. Fields of application of the invention are analytical chemistry and medicinal diagnostics.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit amyloidal-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloidal-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods,and pharmaceutical compositions including effective amyloidal-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of PROTEASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit aberrant amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a LIGASE polypeptide, or fragment thereof, and measuring a compound-LIGASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of LIGASE DNA expression agents or LIGASE agonists, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a KINASE polypeptide, or fragment thereof, and measuring a compound-KINASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including phosphorylated kinase substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of KINASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.